Cost of new Alzheimer's drug could put it out of reach for many in Australia

The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it.